Apyx Medical Corporation priced a $10 million underwritten public offering of 2,762,431 shares of its common stock at $3.62 per share on November 18 2025. The offering includes an underwriter option for an additional 414,365 shares and is expected to close on or about November 19 2025.
The pricing follows a strong Q3 2025 earnings report in which the company posted revenue of $12.9 million—up 12% year‑over‑year—and an earnings‑per‑share figure of –$0.05, beating the consensus estimate of –$0.10. Gross margin improved to 64.4% from 60.5% in the prior year, driven largely by the commercial launch of the AYON Body Contouring System, which has received FDA 510(k) clearance and exceeded pre‑order expectations. The company also raised its full‑year 2025 revenue guidance, reflecting confidence in continued demand for its surgical‑aesthetics portfolio.
Apyx’s management indicated that the proceeds from the offering will be used to strengthen working capital, expand sales and marketing efforts, fund capital expenditures, pursue potential acquisitions, and refinance existing debt. These uses align with the company’s strategy to accelerate the adoption of its high‑margin surgical‑aesthetics products, particularly the AYON system, and to support broader growth initiatives.
The offering is being made under a shelf registration statement filed in 2022, and it follows a prior $7 million registered direct offering in November 2024. The company’s ongoing capital‑raising activities underscore its commitment to maintaining financial flexibility while pursuing expansion opportunities.
Overall, the $10 million public offering represents a significant financing step for Apyx Medical, providing the capital needed to sustain its growth trajectory in the competitive surgical‑aesthetics market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.